跳到正文
制药经理人· GxP知识岛·· 14 天前AI 评分64

FDA公布诺和诺德丹麦马尔勒夫基地483检查报告,含2项方法学验证观察

FDA 483:诺和诺德

AI 导读

FDA公布诺和诺德丹麦马尔勒夫基地(FEI 3003037054)的Form FDA 483,列出2项与方法学验证相关的观察。检查日期为2026年4月13日至17日,签发日期为4月17日;观察指出全血稳定性等实验的原始记录缺少支持孵育时间点的时间戳,且确认性run 8与P&A run 9未按SOP Q053698执行。

正文

近日,FDA公布了诺和诺德(Novo Nordisk)丹麦马尔勒夫基地的483检查报告。该基地在FDA登记的类型为生物制药设施(Biopharmaceutical facility),FEI号3003037054,对口单位是CDER/OTS/OSIS/DNDSI。

这份483只有1页、2项观察,指向的都是方法学验证:一是原始记录不全——全血稳定性按1小时、2小时、4小时三个孵育时间点评估,记录里却没有时间戳;二是SOP没有照着做——确认性run 8没有只带入run 7失败的稳定性质控,而是带入了一整套新的;P&A run 9仅凭目测就被拒,FDA现场要求把平均%RE算出来,结果发现这个run本来不该被拒。

下面是483全文对照,英文原文在上,中文译文在下。原文中带灰色遮盖的(b)(4)为FDA依规删除的商业机密信息,译文原样保留。

Form FDA 483 — Inspectional Observations | Novo Nordisk, Malov, Denmark (FEI 3003037054)

FDA Form 483 检查观察项|诺和诺德,丹麦马尔勒夫(FEI 3003037054)

DEPARTMENT OF HEALTH AND HUMAN SERVICES / FOOD AND DRUG ADMINISTRATION

美国卫生与公众服务部/美国食品药品监督管理局

DISTRICT OFFICE ADDRESS AND PHONE NUMBER: FDA Headquarters - White Oak, CDER/OTS/OSIS/DNDSI, 10903 New Hampshire Avenue, Silver Spring, MD 20993; (301) 796-3865. Industry Information: www.fda.gov/oc/industry

辖区地址与电话:FDA总部 White Oak,CDER/OTS/OSIS/DNDSI,10903 New Hampshire Avenue, Silver Spring, MD 20993;电话 (301) 796-3865;行业信息:www.fda.gov/oc/industry

DATE(S) OF INSPECTION: 4/13/2026 - 4/17/2026 | FEI NUMBER: 3003037054

检查日期:2026年4月13日至4月17日|FEI编号:3003037054

TO: Sif Groth Rønn, Associate Vice President, Non-Clinical and Clinical Assay Sciences

报告接收人:Sif Groth Rønn,非临床与临床分析方法科学副总裁(Associate Vice President)

FIRM NAME: Novo Nordisk | STREET ADDRESS: Novo Nordisk Park 1

企业名称:诺和诺德(Novo Nordisk)|地址:Novo Nordisk Park 1

CITY, STATE AND ZIP CODE: DK-2760, Malov, Denmark | TYPE OF ESTABLISHMENT INSPECTED: Biopharmaceutical facility

城市与邮编:丹麦马尔勒夫(Måløv),DK-2760|受检场所类型:生物制药设施

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS, AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

本文件列出FDA代表在检查贵公司设施期间所作的观察项。这些属检查观察项,不代表FDA对贵公司合规状况的最终认定。如对某项观察有异议,或已针对某项观察采取、或计划采取纠正措施,可在检查期间与FDA代表讨论该异议或措施,也可将相关信息提交至上述FDA地址。如有任何问题,请通过上述电话和地址与FDA联系。

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

在对贵公司的检查中,我们观察到:

The following objectionable conditions pertaining to method validation activities conducted in support of drug product (b)(4).

以下是不符合项,涉及为支持制剂(b)(4)所开展的方法学验证活动。

1) Not all method validation activities were documented in source records from study (b)(4) (b)(4). For instance, stability of (b)(4) (b)(4) in whole blood was evaluated after 1-hour, 2-hour, and 4-hour incubation periods at room temperature. However, source records have no time stamps to support the incubation time points. A similar finding was observed in the shipping and short-term stability experiments.

1)并非所有方法学验证活动都在(b)(4)研究的原始记录中得到记录。例如,(b)(4)(b)(4)在全血中的稳定性,是在室温下孵育1小时、2小时和4小时后评估的;但原始记录中没有时间戳,无法支持这些孵育时间点。在运输稳定性和短期稳定性实验中,也发现了同类问题。

2) Existing standard operating procedures (SOPs) were not always followed during the conduct of method validation experiments. For instance,

2)在方法学验证实验的实施过程中,现行标准操作规程(SOP)并未始终得到遵循。例如:

2a. SOP Q053698, Section 9.8.2, states that only failed stability QCs should be included in subsequent confirmatory runs. Yet, confirmatory run 8 included a new full set of stability QCs instead of including only failing stability QCs from run 7.

2a. SOP Q053698第9.8.2节规定,后续确认性运行中只应纳入失败的稳定性质控(QC)样品。然而,确认性run 8纳入了一整套全新的稳定性质控,而不是只纳入run 7中失败的那部分。

2b. SOP Q053698, Section 5.1, states that an average percent relative error (%RE) should be calculated for each concentration (QC) level and used to accept or reject precision and accuracy (P&A) runs. Additionally, a P&A run should be rejected if the average %RE value exceeds 25% at LLOQ and ULOQ levels and 20% at all other QC levels. Yet, P&A run 9 was rejected based on visual assessment instead of a calculated average %RE value. At my request, average %RE values were calculated during the inspection, and it was discovered that run 9 was incorrectly rejected because the average %RE value was (b)(4) at all QC levels.

2b. SOP Q053698第5.1节规定,应对每个浓度(质控)水平计算平均百分比相对误差(%RE),并据以判定精密度与准确度(P&A)运行是接受还是拒绝。此外,如果平均%RE值在定量下限(LLOQ)和定量上限(ULOQ)水平超过25%、在其他所有质控水平超过20%,该P&A运行应被拒绝。然而,P&A run 9是按目测评估被拒的,并未计算平均%RE值。应本人(检查员)要求,检查期间计算了平均%RE值,结果发现run 9是被错误拒绝的——其平均%RE值在所有质控水平均为(b)(4)。

Signature and Issue

签名与签发

EMPLOYEE(S) SIGNATURE: Ruben C. Ayala -S- (digitally signed 2026.04.17 10:34:24 +0700)

检查员签名:Ruben C. Ayala(电子签名,时间2026年4月17日10:34:24,时区+0700)

EMPLOYEE(S) NAME AND TITLE: Ruben C. Ayala, PharmD, Lead Pharmacokineticist

姓名与职务:Ruben C. Ayala,药学博士(PharmD),首席药代动力学专家

DATE ISSUED: 04/17/2026 | Page 1 of 1 | SEE REVERSE OF THIS PAGE

签发日期:2026年4月17日|共1页|见本页背面

Notes on Names, Terms, and Redactions

译注:名称、术语与脱敏

Novo Nordisk, Malov, Denmark

中文名为"诺和诺德"(Novo Nordisk A/S),总部位于丹麦;受检基地在哥本哈根西北的马尔勒夫(Måløv,原件拼作Malov),地址Novo Nordisk Park 1,邮编DK-2760。该基地在FDA登记的类型为生物制药设施(Biopharmaceutical facility)。

(b)(4)

FDA依规删除的商业机密/保密信息,原件以灰色遮盖块标注(b)(4),译文原样保留,不作推测。被删内容涉及具体产品、研究编号与实测%RE数值。

P&A, %RE, LLOQ, ULOQ

P&A即precision and accuracy(精密度与准确度);%RE即percent relative error(百分比相对误差),原文指各浓度水平平均%RE;LLOQ/ULOQ分别为定量下限与定量上限。stability QC指稳定性考察用的质控样品;confirmatory run指确认性运行。

Personal names

Sif Groth Rønn、Ruben C. Ayala 按原文保留,不擅自给出汉字写法。

Nature of the document

Form FDA 483是检查结束时签发的检查观察项清单,不是最终认定,也不等同于警告信。

来源:制药经理人 · mp.weixin.qq.com

所属事件

查看事件全部
FDA公开诺和诺德Måløv场所483检查观察